Gilead-Teva IP Deal Struck Despite Invalidity Issues, Jury Told
By Dorothy Atkins · June 9, 2023, 11:31 PM EDT
Two experts took the stand Friday on behalf of indirect drug buyers in a California federal antitrust trial over claims Teva struck an illegal "pay for delay" patent deal with Gilead...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login